The Cancer Money Trail: Who Receives the Cancer Research Money?
The money does not stop when the cheque is written. Follow the trail from funders to institutions, researchers and projects.
Knowing which countries contribute is not enough. A country can receive billions in research funding without telling us which organisations received it, which scientists led the work, what the money paid for, or what happened to the results.
The basic chain
The money trail can be represented as:
FUNDER → INSTITUTION → RESEARCHER → PROJECT → OUTPUT
The output may be a publication, dataset, clinical result, research tool, invention, patent, treatment approach or simply knowledge that helps another project. There is no guarantee that every grant produces a commercial product or a medical breakthrough.
NCI cancer centres provide a concrete example
NCI's FY2025 cancer-centre data show 75 cancer centres receiving combined funding of approximately $346.5 million, including about $340.9 million in core grants. This is one identifiable slice of NCI funding rather than the entire U.S. cancer-centre economy.
The purpose of following this type of award is not to suggest that the institution “gets the money” as unrestricted profit. Grants support defined programmes and eligible costs, and the institution administers the award under federal rules.
What can a research grant actually pay for?
Research funding can support staff salaries, laboratory equipment, materials, software, data collection, statistical analysis, patient recruitment, clinical research, training and infrastructure. Some awards support early-career researchers or shared facilities rather than a single experiment.
That makes the trail more complicated than a simple cash transfer. One award can create capacity that supports multiple projects, while a project can combine money from several funders.
Universities are not just buildings
University research systems contain departments, hospitals, laboratories, technology-transfer offices and individual investigators. The same institution can receive government grants, charitable awards and commercial contracts at the same time.
For this reason, a university's total research budget should not automatically be described as cancer funding. The investigation needs to identify the particular cancer award or programme and then determine what the award was intended to support.
Following the researcher
Federal award records can identify principal investigators and recipient institutions. Publications can then provide another link in the chain by showing what research was produced and which investigators were involved.
But publication is not the same as impact. A paper can be scientifically important without producing a patent, a clinical trial or a product. Conversely, an important discovery can take years to move from a paper into practical use.
Charitable funding follows a similar path
Cancer Research UK supports research at major institutions including the Francis Crick Institute, universities and specialist cancer centres. Its grant programmes show how philanthropic funding can support investigator-led science, infrastructure and training.
Again, a charity award should not be confused with an institution's entire cancer budget. The relevant question is what the specific grant supports and what obligations attach to it.
When research becomes an invention
Sometimes research produces something that can be protected as intellectual property. Under the Bayh-Dole framework, qualifying recipients of federally supported research can, subject to statutory and regulatory requirements, retain rights to certain inventions. In return, recipients have reporting and commercialisation responsibilities, while the federal government retains specified rights.
NIH guidance requires inventions arising from federally funded projects to be reported. Recipients may elect to retain title, file for patent protection and report progress toward practical application. These rules create a paper trail that can extend beyond the original grant.
But a patent is not a treatment
A patent is a legal instrument. It can protect an invention, but it does not establish that a cancer treatment works in patients. A licence transfers defined rights under an agreement, but it does not prove that a commercial product reached the market.
Likewise, a research grant does not prove that a discovery was successful. A publication does not guarantee clinical benefit. A clinical trial does not guarantee regulatory approval. Each stage needs separate evidence.
Commercialisation can require new money
Even when a discovery has public or charitable origins, later development can require additional capital. Companies may fund manufacturing, toxicology, clinical development, regulatory work, supply chains and market preparation. Public institutions may also continue to contribute through later grants or collaborations.
This is why the money trail should not be described as a straight line from taxpayers to pharmaceutical revenue. It is usually a chain of different funding decisions, organisations, contracts, risks and ownership arrangements.
The next step
Part 5 follows the trail into patents, licences and commercial development. The aim is not to claim that commercialisation is inherently good or bad. It is to establish what the records actually show when publicly supported research crosses into intellectual property and industry.
Both sides. One record. Evidence before conclusions. Primary sources are prioritised. Facts, estimates and uncertainty are distinguished, and figures are not combined when their definitions, periods or coverage are materially different.